PharmaWeek - Sept. 10, 2008
Wed., Sept. 10, 2008 | | Archives | Advertising | Your Account | CHI Conferences |  Subscribe |
Sales Contacts
For advertising information contact: 

Alan El Faye
VP, Advertising Sales - CA, Western US, Midwest, South Eastern US, Europe, Canada, Pacific Rim

Kay O. Christopher
Regional Sales Manager, Advertising Sales -New England, North Eastern US

Tom Loughran
Regional Sales Manager, Advertising Sales -Midwest, South Eastern US, Europe

Contact the Editor
PharmaWeek welcomes your feedback. Please contact Catherine Varmazis or Allison Proffitt for editorial inquiries. 

Link to Us! 
You are welcome to link to articles on our website. Contact Catherine Varmazis for details.

e-Prints & Reprints 
To post a full article from PharmaWeek or Bio-IT World on your website (not just a link), or for paper reprints, please contact:
Ashley Zander

The YGS Group
717-399-1900 ext.125

Dear Colleague,
Welcome to this week's eNewsletter covering breaking R&D news, business insights, and a feature on BMS' plan to become a 'next-gen' pharma.


Amylin's Byetta Tops Merck's Januvia in Diabetes Test
Bloomberg [Sept. 9] Amylin Pharmaceuticals’ diabetes treatment Byetta worked better than Merck & Co.’s Januvia in tests that measured blood-sugar levels after meals in 61 patients who tried each drug for two weeks. More

Pfizer Tries Again with Osteoporosis Drug Fablyn
Wall Street Journal blog [Sept. 9] Pfizer’s going before an FDA panel today to try to win approval of a bone drug that’s already been rejected twice. The drug, called Fablyn, is in the same class as Eli Lilly’s osteoporosis drug Evista. More

Novartis Cancer Drug Wins U.S. Priority Review
Press release [Sept. 9] Novartis announced that RAD001 (everolimus) has been granted priority review by the US Food and Drug Administration (FDA). The designation is based on the drug's potential to become the first therapy to demonstrate significant benefit in patients with advanced kidney cancer after failure of standard treatment. More

Studies Spot Numerous Undiscovered Gene Alterations in Pancreatic and Brain Cancers
HHMI News [Sept. 4] HHMI investigators have detected a multitude of broken, missing, and overactive genes in pancreatic and brain tumors, in the most detailed genetic survey yet of any human tumor. More

Biogen and Elan Start Testing Tysabri in Cancer
Boston Globe [Sept. 5] Biogen Idec Inc. and Elan Corp. PLC said they have started the first clinical trial of their multiple sclerosis and Crohn's disease drug Tysabri as a treatment for cancer. More

Regeneron's Drug to Lower Gout Flares Meets Goal
Reuters [Sept. 3] Regeneron Pharmaceuticals Inc. said its experimental treatment to reduce gout flares, Arcalyst, met the main goal in a mid-stage trial and reduced flares by 81 percent, sending its shares up as much as 15 percent. More


Broad Institute Secures Future with $400 Million Endowment
Source [Sept. 4] Billionaire philanthropist Eli Broad and his wife Edythe have announced a new $400 million endowment that secures the future of the Broad Institute. More

Outsourcing the Drug Industry
BusinessWeek [Sept. 4] U.S. giants are rushing to partner with Indian and Chinese companies—tapping their brainpower and saving millions of dollars in the search for breakthrough treatments. More

New Boss Aids Sanofi's American Dream
Forbes [Sept. 10] The revelation that GlaxoSmithKline's Chris Viehbacher would take the top spot at France's Sanofi-Aventis gave a boost to Sanofi's shares on Wednesday, with the new boss likely to revamp the pharmaceutical firm's position in the United States and bolster its strength in emerging markets. More

Pfizer Acquires Rights to Alzheimer's Drug
New York Times [Sept. 4] Pfizer said Wednesday that it was acquiring the rights to a promising experimental drug for Alzheimer’s disease from Medivation for as much as $725 million. More

Big Pharma Gravitates to the Academe
Financial Times [Sept. 2] Beset by drug failures and limited late-stage pipelines, big pharmaceutical companies are increasingly looking outside their own walls for scientific discoveries by partnering with academic institutions. More

Judge to Unseal Documents on the Eli Lilly Drug Zyprexa
New York Times [Sept. 5] A federal judge in Brooklyn decided on Friday to unseal confidential materials about Eli Lilly’s top-selling antipsychotic drug Zyprexa, citing “the health of hundreds of thousands of people” and “fundamental questions” about the way drugs are approved for new uses. More


Amylin Reports Four Deaths, Stocks Fall
Forbes [Aug. 28] On August 26, Amylin and Eli Lilly announced four new deaths in patients taking their jointly-developed type 2 diabetes drug Byetta. The deaths follow an FDA warning issued to doctors and patients reporting cases of pancreatitis and death. After the announcement, Amylin shares fell more than 25%, while Lilly shares held. On Thursday, Amylin had rebounded about 6%. More.

For More Recent Articles >>



Isilon Systems ~ Senior Marketing Communications Manager
Isilon Systems is the worldwide leader in clustered storage systems and software for digital content and unstructured data. We seek an experienced marketing communications professional/writer expert in creating and delivering effective and persuasive business communications. The ideal candidate can think at the strategic and conceptual level and act, simultaneously, as a highly-effective and productive individual contributor. The position is based in Seattle, WA. For additional information
 click here

Lilly Singapore Center for Drug Discovery (LSCDD) - Associate Director of Informatics,
Lead and mentor a strong team for the Bioinformatics group at the Integrative Computational Sciences (ICS) department at LSCDD towards the development of novel algorithms, data analysis methods and software tools for drug discovery. Work closely with the Software Engineering group at ICS, and collaborate with the Discovery IT organization in Europe and USA. For additional information, or to apply visit:

Lilly Singapore Center for Drug Discovery (LSCDD)- Senior Bioinformatics Scientist,
Contribute to the development of novel algorithms, data analysis methods and software tools for drug discovery as part of the Integrative Computational Sciences (ICS) department at LSCDD.  Work closely with informatics and software engineering peers at ICS, and collaborate with the Discovery IT organization in Europe and USA. The successful candidate will offer hands-on insight and expertise in tailored therapeutic informatics and statistical analyses at the post-genomic era. For additional information, or to apply visit:

Lilly Singapore Center for Drug Discovery (LSCDD) - Manager, Software Engineering (Integrative Computational Sciences)
Join the Integrative Computational Sciences (ICS) department at Lilly Singapore Centre for Drug Discovery (LSCDD),as Manager Software Engineering.  Lead the development of integrated applications to process and visualize data from cutting edge technologies used by scientists at Lilly Research Labs (LRL) and the Drug Discovery Research (DDR) teams. Masters in Computer Science/Engineering or related discipline, 10+ years post graduation experience , 2 years management experience needed. For a complete job description and requirements or to apply visit:

Lilly Singapore Center for Drug Discovery(LSCDD) -Senior Software Engineer, 
Join a strong team of software engineers in our Integrative Computational Sciences (ICS) at LSCDD. Collaborate with, and help develop integrated applications to process and visualize data from cutting-edge technologies used by scientists at Lilly Research Labs (LRL) and the Drug Discovery Research (DDR) teams. The Software Engineering team provides computational tools and tailored software solutions that enable the global effort of Tailored Therapeutics; ‘The Right Drug, at The Right Dose for The Right Patient at The Right Time'. For additional information, or to apply visit:

Memorial Sloan-Kettering Cancer Center - Linux Systems Administrator
MSKCC Bioinformatics Core in Manhattan seeks Linux Systems Administrator. Install, configure, update, monitor and troubleshoot HPC cluster, email and web servers. Bachelor's degree and 3 years experience with HPC, network security, Postfix, Apache, Tomcat, Grid Engine, Solaris. Email #015429. EOE/AA

More Life Science Jobs ~ Add a Job Listing



ELNs: Advanced Laboratory Solutions-September 15 - 17 2008 • Crowne Plaza, Brussels, Belgium 

Discovery Knowledge & Informatics - September 15 - 17, 2008 • Crowne Plaza, Brussels, Belgium 

Multiplexed Genomics Tools: Targeting the Missing Links
Between Health and Disease - September 21-23, 2008 • Providence, RI

Next-Generation Sequencing Data Analysis -September 22-23, 2008 • Providence, RI

DIA 2nd Annual Clinical Forum: Data Driven Drug Development Decisions - October 20-23, 2008 | Ljubljana, Slovenia

The Fifteenth Annual Biopharmaceutical Applied Statistics Symposium - Nov 3-7,2008~ Savannah, GA

Barnett Educational Services, 2008 Schedule

To have your event featured here, contact Lynn Cloonan for more information.

 Email to a Friend 


Bristol-Myers Squibb Seeks to Become 'Next-Generation Pharma'
By Allison Proffitt

Sept 9, 2008 | Adopting a more agile biotech philosophy and an acquisition strategy akin to creating “a string of pearls” are the key ingredients to helping Bristol-Myers Squibb succeed as a next-generation pharma, according to CSO and president of R&D, Elliott Sigal.

Sigal, who keynoted DDT in August, believes the industry’s current challenges are important, but surmountable. Sigal graduated from medical school in 1981 and began a career spanning medicine, research, and management. Before joining BMS in 1997, he held positions at pharmaceutical company Syntex and the genomics firm Mercator Genetics.

From this vantage point, he sees the challenges facing biotech clearly: patent expiration, greater clinical and regulatory requirements, increased role of payers, and “a severe restriction of access to capital.” But he also sees much opportunity at this juncture.

“I’m speaking primarily from the standpoint of a mid-size pharma company,” he says. “We wonder whether the traditionally do-it-all, own-it-all from every part of the value chain is sustainable. It’s certainly a risky and costly model.” Read More


Life Science Webcasts from Bio-IT World and Cambridge Healthtech Media Group

Life Science Webcasts

Bio-IT World Expo
Video Highlights

Drug Discovery, Development and Commercialization: Evolving Challenges and Opportunities
Joshua Boger, PhD, president and CEO, Vertex Pharmaceuticals Inc., delivers his keynote at the 2008 Bio-IT World Conference & Expo in Boston, April 2008.
View the Webcast Now.

Personalized Genetics: Advancements and Driving Change
Linda Avey, co-founder of 23andMe, delivers her keynote at the 2008 Bio-IT World Conference & Expo in Boston, April 30, 2008.
View the Webcast Now.

The Future of Personal Genomics
A distinguished panel of personal genomics experts discuss the future of personal genomics at the 2008 Bio-IT World Conference & Expo in Boston, April 30, 2008.  They include Dietrich Stephan (co-founder, Navigenics); George Church (Harvard Medical School);
Jeff Drazen (editor-in-chief, New England Journal Medicine); Fred Ledley (Bentley College); John Halamka (CIO, Harvard Medical School); and Linda Avey (23andMe). Bio-IT World Editor-in-Chief Kevin Davies moderates the discussion.
View the Webcast Now

Insight Pharma Reports

Strategic Management of Resources and Portfolios

Analyzes ways that risks can be assessed and managed, how corporate resources can be allocated to create maximum value, models for optimal portfolio planning and management.
More Information 

Custom Market Research Services
Our experienced research team will work with you to fully understand your needs in order to create and conduct a custom market research program that meets your objectives.
Learn More

Featured Content

“Storage for Science – Methods for Managing Large and Rapidly Growing Data Stores in Life Science Research Environments” sponsored by Isilon
Large and rapidly growing stores of file-based and other data are a hallmark of life science research and bioinformatics. Determining how best to manage those data stores has become a significant challenge for Researchers and IT Pros alike.  This paper is intended to:  Provide guidance on the many storage  requirements common to Life Science research;  Explain the evolution of modern storage architectures; Summarize the major data storage architectures currently in use.  Additionally, it will present the Isilon IQ clustered storage product as a strong and flexible solution to those needs. Download now      

Will Healthcare IT Trends Standardize?
A new wave of activities are driving transformation within the healthcare market. One solution is found in a guide to PDF Healthcare Best Practices. This “Best Practices Guide” describes Portable Document Format (PDF) attributes and use to facilitate the capture, exchange, preservation and protection of healthcare information. This webinar will focus on trends in today’s healthcare market, the challenges in overcoming these issues, and finally how to use best practices to improve patient care, enhance productivity and eliminate paperwork. It’s hosted by Adobe and moderated by Digital Healthcare & Productivity Executive Editor, John Russell. Click here... 

To have your white paper featured here, contact Lynn Cloonan for more information.

                                Healthtech InstitutePublished by Cambridge Healthtech Institute (CHI). Copyright © 2008, all rights reserved. No material may be reproduced electronically or in print without written permission from CHI, 250 First Ave., Needham, MA 02494-2814. For reprints and/or copyright permission, please contact The YGS Group, 1808 Colonial Village Lane, Lancaster, PA; 17601 717-399-1900 ext.125, or email: